Page last updated: 2024-12-07

1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid, also known as **(1S,3S)-1-amino-3-(phosphonomethyl)cyclobutane-1-carboxylic acid** or simply **phosphono-γ-aminobutyric acid** (**PγAB**), is a unique and powerful amino acid analog that has garnered considerable attention in research.

Here's why it's important:

**1. Structural Novelty:**
* PγAB is a **non-natural amino acid** that incorporates a phosphonate group (PO3H2), which is rarely found in naturally occurring amino acids.
* This unusual structure makes it an excellent tool for studying the effects of phosphonates on biological processes.

**2. GABA Analog:**
* It is structurally similar to **γ-aminobutyric acid (GABA)**, a major inhibitory neurotransmitter in the brain. This similarity allows PγAB to act as a **GABA analog**, potentially affecting neurotransmission.

**3. Potential Therapeutic Applications:**
* Due to its GABA analog properties, PγAB has been explored for its potential to:
* **Treat neurological disorders:** Research suggests that PγAB might be helpful in managing epilepsy, anxiety disorders, and Parkinson's disease.
* **Enhance cognition:** PγAB's impact on GABAergic signaling could potentially improve cognitive function.
* **Fight cancer:** PγAB has shown promise in inhibiting tumor growth and promoting apoptosis (programmed cell death) in certain cancer cells.

**4. Research Tool:**
* As a non-natural amino acid, PγAB is valuable in various research applications:
* **Probe protein-ligand interactions:** Its unique structure allows researchers to study how proteins interact with phosphonate-containing molecules.
* **Develop new pharmaceuticals:** PγAB's structural characteristics can be used as a template for designing novel drugs with improved therapeutic effects.

**5. Ongoing Research:**
* The research on PγAB is still ongoing, with ongoing efforts to:
* Understand its precise mechanism of action in different biological systems.
* Develop safe and effective therapeutic strategies based on PγAB.
* Explore its potential applications beyond its known uses.

**Key Takeaways:**

* 1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid (PγAB) is a unique and important non-natural amino acid analog.
* Its structural similarity to GABA and its phosphonate group make it a valuable tool for investigating various biological processes.
* PγAB holds potential for therapeutic applications, particularly in neurological disorders and cancer treatment.
* Ongoing research continues to explore its full potential and develop its applications.

1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid: potently inhibits evoked field potentials in the rat lateral perforant path; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126582
CHEMBL ID22136
SCHEMBL ID7820968
MeSH IDM0202831

Synonyms (11)

Synonym
cyclobutylene ap5
bdbm50089105
1-amino-3-phosphonomethylene-cyclobutanecarboxylic acid
CHEMBL22136 ,
1-amino-3-(phosphonomethylidene)cyclobutane-1-carboxylic acid
cyclobutanecarboxylic acid, 1-amino-3-(phsophonomethylene)-, (+-)-
(+-)-1-amino-3-(phsophonomethylene)cyclobutanecarboxylic acid
140480-88-2
1-amino-3-(phosphonomethylene)cyclobutane-1-carboxylic acid
SCHEMBL7820968
PD075299
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Metabotropic glutamate receptor 4Rattus norvegicus (Norway rat)EC50 (µMol)4.50000.00902.54409.4900AID109469
Metabotropic glutamate receptor 4Homo sapiens (human)EC50 (µMol)4.40000.00401.71939.8000AID109331
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
adenylate cyclase-inhibiting G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 4Homo sapiens (human)
chemical synaptic transmissionMetabotropic glutamate receptor 4Homo sapiens (human)
neurotransmitter secretionMetabotropic glutamate receptor 4Homo sapiens (human)
positive regulation of MAPK cascadeMetabotropic glutamate receptor 4Homo sapiens (human)
regulation of neuron apoptotic processMetabotropic glutamate receptor 4Homo sapiens (human)
regulation of synaptic transmission, glutamatergicMetabotropic glutamate receptor 4Homo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
glutamate receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
adenylate cyclase inhibiting G protein-coupled glutamate receptor activityMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
plasma membraneMetabotropic glutamate receptor 4Rattus norvegicus (Norway rat)
plasma membraneMetabotropic glutamate receptor 4Homo sapiens (human)
cytoplasmic vesicleMetabotropic glutamate receptor 4Homo sapiens (human)
presynapseMetabotropic glutamate receptor 4Homo sapiens (human)
plasma membraneMetabotropic glutamate receptor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID92184Antagonistic activity against 5 uM of quis/AMPA at the concentration of 100 uM1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids.
AID93413Antagonistic activity against Ionotropic glutamate receptor kainate at the concentration of 100 uM1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids.
AID109469Effective concentration against rat Metabotropic glutamate receptor 42000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
(+)-4-phosphonophenylglycine (PPG) a new group III selective metabotropic glutamate receptor agonist.
AID144188Antagonistic activity against 10 uM of N-methyl-D-aspartate glutamate receptor at the concentration of 100 uM1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids.
AID109331Agonistic activity at Metabotropic glutamate receptor 4 expressed in mammalian cells by GTPgammaS binding assay2000Bioorganic & medicinal chemistry letters, Jul-03, Volume: 10, Issue:13
Synthesis, molecular modeling and preliminary biological evaluation of 1-amino-3-phosphono-3-cyclopentene-1-carboxylic acid and 1-amino-3-phosphono-2-cyclopentene-1-carboxylic acid, two novel agonists of metabotropic glutamate receptors of group III.
AID144194Depression of depolarizing response vs 10 uM N-methyl-D-aspartate glutamate receptor at the concentration of 500 uM; inactive1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Synthesis and activity of a potent N-methyl-D-aspartic acid agonist, trans-1-aminocyclobutane-1,3-dicarboxylic acid, and related phosphonic and carboxylic acids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's3 (50.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.24 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]